Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?

Abstract

Background The endocannabinoid (eCB) system, an endogenous lipid signaling system, appears to be dysregulated in depression. The role of endocannabinoids (eCBs) as potent immunomodulators, together with the accumulating support for a chronic low-grade inflammatory profile in depression, suggests a compelling hypothesis for a fundamental impairment in their intercommunication, in depression. Objective We aim to review previous literature on individual associations between the immune and eCB systems and depression. It will focus on peripheral and central mechanisms of crosstalk between the eCB and immune systems. A potential dysregulation in this crosstalk will be discussed in the context of depression. Results Investigations largely report a hypoactivity of the eCB system and increased inflammatory markers in individuals with depression. Findings depict a multifaceted communication whereby immunocompetent and eCB-related cells can both influence the suppression and enhancement of the other's activity in both the periphery and central nervous system. A dysregulation of the eCB system, as seen in depression, appears to be associated with central and peripheral concentrations of inflammatory agents implicated in the pathophysiology of this illness. Conclusion The eCB and immune systems have been individually associated with and implicated in pathogenic mechanisms of depression. Both systems tightly regulate the other's activity. As such, a dysregulation in this crosstalk has potential to influence the onset and maintenance of this neuropsychiatric illness. However, few studies have investigated both systems and depression conjointly. This review highlights the demand to consider joint eCB-immune interactions in the pathoetiology of depression.

Serum endocannabinoids and N-acyl ethanolamines and the influence of simulated solar UVR exposure in humans in vivo

“…[27][28][29] They are active in neurotransmission in the central and peripheral nervous systems, including reduction in pain perception via CB1 and transient receptor potential vanilloid-1 receptors (TRV-1), 30 and show anti-inflammatory/immune-modulatory effects via peripheral CB2 receptors, including reduced IFN- and increased IL-10 secretion. 31 Although CB1 receptors were traditionally described in the central nervous system and CB2 peripherally as in immune cells, it has become evident their distribution is more variable and widespread throughout organ systems, including skin 21,32-33 which has been shown to possess a functional endocannabinoid system. 17 CB1 and CB2 receptors are expressed by keratinocytes and melanocytes, and also identified in sebocytes and hair follicles.…”

Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: a preliminary study

“…Mounting evidence of immune imbalance in affective disorders has sprung up in recent decades, pointing to a role of inflammatory burden in affected patients12. The crosstalk between inflammatory abnormalities and affective disorders has been extensively investigated from various perspectives, including cytokines, chemokines, antibody titers and immune cell numbers34567.…”

Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis

“…CT scans were acquired prior to each PET scan for correction of attenuation and scatter. Continuous arterial blood sampling took place for the first 15 minutes of the scan which was followed by discrete blood sampling at 2,5,10,15,20,25,35,40,50,60,70,80 and 90 minutes after radioligand injection.…”